Tag: XNCR

Finance

Biotech Gainers: Xencor Inc (NASDAQ:XNCR), Pacific Biosciences of California (NASDAQ:PACB), Endocyte (NASDAQ:ECYT), Incyte Corporation (NASDAQ:INCY)

Xencor, Inc. (NASDAQ:XNCR) is unchanged at $11.73, with 934,368 shares traded. As reported by Zacks, the current mean recommendation for XNCR is in the “strong buy range”. Xencor Inc (NASDAQ:XNCR) stock performance was 11.18% in last session and finished the day at $11.73. Traded volume was 1.86million shares in the last session and the average volume of the stock remained 132.02K shares. Xencor Inc (NASDAQ:XNCR) … Continue reading Biotech Gainers: Xencor Inc (NASDAQ:XNCR), Pacific Biosciences of California (NASDAQ:PACB), Endocyte (NASDAQ:ECYT), Incyte Corporation (NASDAQ:INCY)

Kevin Long
Finance

Biotech Unusual Volume: Capstone Therapeutics (OTCMKTS:CAPS), Xencor (NASDAQ:XNCR), Durata Therapeutics (NASDAQ:DRTX), Clovis Oncology (NASDAQ:CLVS)

Capstone Therapeutics Corp. (OTCMKTS:CAPS) and its joint venture affiliate, LipimetiX Development, LLC (“JV”), today will hold a conference call and webcast to provide an operating update, discuss the start of AEM-28 Phase 1 clinical studies and report financial results for the fiscal year 2013. Capstone Therapeutics Corp. (OTCMKTS:CAPS) stock performance was 4.00% in last session and finished the day at $0.260. Traded volume was 57,580.00million … Continue reading Biotech Unusual Volume: Capstone Therapeutics (OTCMKTS:CAPS), Xencor (NASDAQ:XNCR), Durata Therapeutics (NASDAQ:DRTX), Clovis Oncology (NASDAQ:CLVS)

Kristen Barton
BioTech

Biotech Stocks Touching New Highs: Relypsa Inc. (NASDAQ:RLYP), Vanda Pharmaceuticals (NASDAQ:VNDA), OHR Pharmaceutical (NASDAQ:OHRP), Xencor (NASDAQ:XNCR)

Relypsa, Inc. (NASDAQ:RLYP) is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. Relypsa Inc. (NASDAQ:RLYP) stock performance was 2.66% in last session and finished the day at $43.62. Traded volume was 126,739.00 shares in the last session and the average volume of the stock remained 113,686.00 shares. Relypsa … Continue reading Biotech Stocks Touching New Highs: Relypsa Inc. (NASDAQ:RLYP), Vanda Pharmaceuticals (NASDAQ:VNDA), OHR Pharmaceutical (NASDAQ:OHRP), Xencor (NASDAQ:XNCR)

Mark DeFrance
BioTech

Biotech Overbought Socks: Xencor Inc. (NASDAQ:XNCR), Albany Molecular Research (NASDAQ:AMRI), Oncothyreon (NASDAQ:ONTY), OXiGENE Inc. (NASDAQ:OXGN)

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2013 financial results after market close on Wednesday, March 19, 2014. Xencor Inc. (NASDAQ:XNCR) stock performance was -1.58% in last session and finished the day at $13.68. Traded volume was 99,904.00 shares … Continue reading Biotech Overbought Socks: Xencor Inc. (NASDAQ:XNCR), Albany Molecular Research (NASDAQ:AMRI), Oncothyreon (NASDAQ:ONTY), OXiGENE Inc. (NASDAQ:OXGN)

Jayne Crisman
BioTech

Biotech Stocks Touching New Highs: Northwest Biotherapeutics (NASDAQ:NWBO), OncoGenex Pharmaceuticals (NASDAQ:OGXI), Emergent Biosolutions (NYSE:EBS), Xencor (NASDAQ:XNCR)

CRT Capital Thursday morning ratings report included a coverage initiation by analyst Arlinda Lee on Oncogenex Pharmaceuticals (NASDAQ: OGXI) with a Buy rating and price target of $20. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) rose 8.88 percent to $13.85 yesterday on volume of 483,342million shares. The intra-day range of the stock was $12.61 to $13.95. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) has a market capitalization of $203.70million. Emergent Biosolutions … Continue reading Biotech Stocks Touching New Highs: Northwest Biotherapeutics (NASDAQ:NWBO), OncoGenex Pharmaceuticals (NASDAQ:OGXI), Emergent Biosolutions (NYSE:EBS), Xencor (NASDAQ:XNCR)

John Meady